The SAlzburg PEritoneal SUrface CAlculator (SAPESUCA): The First Web-Based Application for Peritoneal Surface Area Quantification.
R Shiny app
cytoreductive surgery
hyperthermic intraperitoneal chemotherapy
intraperitoneal drug dosing
peritoneal cancer index
peritoneal metastases
peritoneal surface area
peritoneal surface malignancies
web-based application
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
10 Jun 2023
10 Jun 2023
Historique:
received:
16
02
2023
revised:
05
05
2023
accepted:
05
06
2023
medline:
28
6
2023
pubmed:
28
6
2023
entrez:
28
6
2023
Statut:
epublish
Résumé
(1) Background: Peritoneal metastasized colorectal cancer is associated with a worse prognosis. The combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) showed promising results in selected patients, but standardization is lacking so far. We present the first tool enabling standardized peritoneal surface area (PSA) quantification in patients undergoing CRS and HIPEC: The SAlzburg PEritoneal SUrface CAlculator (SAPESUCA). (2) Methods: SAPESUCA was programmed using the R-Shiny framework. The application was validated in 23 consecutive colon cancer patients who received 27 closed oxaliplatin-based HIPECs between 2016 and 2020. The programming algorithm incorporates the patient's body surface area and its correlated peritoneal surface area (PSA) based on the 13 Peritoneal Cancer Index (PCI) regions. (3) Results: Patients' median age was 56 years. Median PCI was 9. SAPESUCA revealed a mean PSA of 18,613 cm
Identifiants
pubmed: 37370744
pii: cancers15123134
doi: 10.3390/cancers15123134
pmc: PMC10296656
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Österreichische Krebshilfe Salzburg, Salzburg, Austria
ID : 24.11.2020
Références
Lancet Oncol. 2016 Dec;17(12):1709-1719
pubmed: 27743922
Ann Surg Oncol. 1999 Dec;6(8):790-6
pubmed: 10622509
Lancet Oncol. 2020 Sep;21(9):1147-1154
pubmed: 32717180
Orphanet J Rare Dis. 2021 Feb 13;16(1):85
pubmed: 33581733
Eur J Surg Oncol. 2019 Mar;45(3):400-402
pubmed: 30392745
Cancers (Basel). 2019 Jan 11;11(1):
pubmed: 30641919
Cancer. 2006 Mar 1;106(5):1144-53
pubmed: 16456817
J Clin Oncol. 2003 Oct 15;21(20):3737-43
pubmed: 14551293
Indian J Surg Oncol. 2016 Jun;7(2):225-9
pubmed: 27065713
Surg Radiol Anat. 2009 Jun;31(5):369-77
pubmed: 19142561
Br J Surg. 2012 May;99(5):699-705
pubmed: 22287157
Hepatogastroenterology. 1994 Apr;41(2):124-9
pubmed: 8056398
Ann Surg Oncol. 2004 Apr;11(4):387-92
pubmed: 15070598
Ann Surg Oncol. 2005 Nov;12(11):910-8
pubmed: 16177862
Ann Oncol. 2002 Feb;13(2):267-72
pubmed: 11886004
Cancer Treat Rep. 1978 Jan;62(1):1-11
pubmed: 626987
Ann Surg Oncol. 2004 Feb;11(2):178-86
pubmed: 14761921
J Clin Oncol. 2012 Jan 20;30(3):263-7
pubmed: 22162570
Lancet Oncol. 2021 Feb;22(2):256-266
pubmed: 33476595
Cancer Epidemiol. 2014 Aug;38(4):448-54
pubmed: 24841870
Ann Surg Oncol. 2003 Oct;10(8):863-9
pubmed: 14527903
Int Semin Surg Oncol. 2005 Feb 08;2(1):3
pubmed: 15701175
Eur J Surg Oncol. 2021 Jan;47(1):36-59
pubmed: 32209311
Eur J Surg Oncol. 2017 Jul;43(7):1228-1235
pubmed: 28189456
J Surg Oncol. 2008 Sep 15;98(4):247-52
pubmed: 18726886
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Pleura Peritoneum. 2020 Feb 26;5(1):20190031
pubmed: 32885035
Ann Surg Oncol. 2021 Dec;28(13):9098-9113
pubmed: 34142293
Lancet Gastroenterol Hepatol. 2019 Oct;4(10):761-770
pubmed: 31371228
Cancer Treat Res. 1996;82:359-74
pubmed: 8849962
Eur J Surg Oncol. 2011 Feb;37(2):148-54
pubmed: 21093205
Br J Surg. 2004 Jun;91(6):739-46
pubmed: 15164445